Aliases & Classifications for Vaginitis

MalaCards integrated aliases for Vaginitis:

Name: Vaginitis 12 42 43 15 71
Infective Vaginitis 71


External Ids:

Disease Ontology 12 DOID:2170
ICD9CM 34 616.1 616.10
MeSH 43 D014627
NCIt 49 C26911
SNOMED-CT 67 30800001
UMLS 71 C0042267 C0042268 C0404521

Summaries for Vaginitis

MedlinePlus : 42 What is vaginitis? Vaginitis, also called vulvovaginitis, is an inflammation or infection of the vagina. It can also affect the vulva, which is the external part of a woman's genitals. Vaginitis can cause itching, pain, discharge, and odor. Vaginitis is common, especially in women in their reproductive years. It usually happens when there is a change in the balance of bacteria or yeast that are normally found in your vagina. There are different types of vaginitis, and they have different causes, symptoms, and treatments. What causes vaginitis? Bacterial vaginosis (BV) is the most common vaginal infection in women ages 15-44. It happens when there is an imbalance between the "good" and "harmful" bacteria that are normally found in a woman's vagina. Many things can change the balance of bacteria, including Taking antibiotics Douching Using an intrauterine device (IUD) Having unprotected sex with a new partner Having many sexual partners Yeast infections (candidiasis) happen when too much candida grows in the vagina. Candida is the scientific name for yeast. It is a fungus that lives almost everywhere, including in your body. You may have too much growing in the vagina because of Antibiotics Pregnancy Diabetes, especially if it is not well-controlled Corticosteroid medicines Trichomoniasis can also cause vaginitis. Trichomoniasis is a common sexually transmitted disease. It is caused by a parasite. You can also have vaginitis if you are allergic or sensitive to certain products that you use. Examples include vaginal sprays, douches, spermicides, soaps, detergents, or fabric softeners. They can cause burning, itching, and discharge. Hormonal changes can also cause vaginal irritation. Examples are when you are pregnant or breastfeeding, or when you have gone through menopause. Sometimes you can have more than one cause of vaginitis at the same time. What are the symptoms of vaginitis? The symptoms of vaginitis depend on which type you have. With BV, you may not have symptoms. You could have a thin white or gray vaginal discharge. There may be an odor, such as a strong fish-like odor, especially after sex. Yeast infections produce a thick, white discharge from the vagina that can look like cottage cheese. The discharge can be watery and often has no smell. Yeast infections usually cause the vagina and vulva to become itchy and red. You may not have symptoms when you have trichomoniasis. If you do have them, they include itching, burning, and soreness of the vagina and vulva. You may have burning during urination. You could also have gray-green discharge, which may smell bad. How is the cause of vaginitis diagnosed? To find out the cause of your symptoms, your health care provider may Ask you about your medical history Do a pelvic exam Look for vaginal discharge, noting its color, qualities, and any odor Study a sample of your vaginal fluid under a microscope In some cases, you may need more tests. What are the treatments for vaginitis? The treatment depends on which type of vaginitis you have. BV is treatable with antibiotics. You may get pills to swallow, or cream or gel that you put in your vagina. During treatment, you should use a condom during sex or not have sex at all. Yeast infections are usually treated with a cream or with medicine that you put inside your vagina. You can buy over-the-counter treatments for yeast infections, but you need to be sure that you do have a yeast infection and not another type of vaginitis. See your health care provider if this is the first time you have had symptoms. Even if you have had yeast infections before, it is a good idea to call your health care provider before using an over-the-counter treatment. The treatment for trichomoniasis is usually a single-dose antibiotic. Both you and your partner(s) should be treated, to prevent spreading the infection to others and to keep from getting it again. If your vaginitis is due to an allergy or sensitivity to a product, you need to figure out which product is causing the problem. It could be a product that you started using recently. Once you figure it out, you should stop using the product. If the cause of your vaginitis is a hormonal change, your health care provider may give you estrogen cream to help with your symptoms. Can vaginitis cause other health problems? It is important to treat BV and trichomoniasis, because having either of them can increase your risk for getting HIV or another sexually transmitted disease. If you are pregnant, BV or trichomoniasis can increase your risk for preterm labor and preterm birth. Can vaginitis be prevented? To help prevent vaginitis Do not douche or use vaginal sprays Use a condom when having sex Avoid clothes that hold in heat and moisture Wear cotton underwear

MalaCards based summary : Vaginitis, also known as infective vaginitis, is related to vaginal discharge and pelvic organ prolapse, and has symptoms including leukorrhea, vaginal pruritus and vaginal odor. An important gene associated with Vaginitis is ESR1 (Estrogen Receptor 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Apricot and Cranberry have been mentioned in the context of this disorder. Affiliated tissues include testes, breast and heart, and related phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and hematopoietic system

Disease Ontology : 12 A vaginal disease that is characterized by inflammation of the vagina.

Wikipedia : 74 Vaginitis, also known as vulvovaginitis, is inflammation of the vagina and vulva. Symptoms may include... more...

Related Diseases for Vaginitis

Diseases related to Vaginitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1525)
# Related Disease Score Top Affiliating Genes
1 vaginal discharge 34.1 SLPI IL6 ESR1 CXCL8 CD4 ATAD2
2 pelvic organ prolapse 33.2 ESR2 ESR1 CCR6
3 vulvovaginal candidiasis 33.2 TLR2 DEFB4A CCR6
4 genital herpes 32.8 TLR2 CD4 CCR6
5 syphilis 32.4 FN1 CD4 CCR6 CCR5
6 human immunodeficiency virus infectious disease 32.4 TNF SLPI CD4 CCR6 CCR5
7 bacterial vaginosis 32.3 TNF TLR2 IL6 IL1B DEFB4A CXCL8
8 chorioamnionitis 32.2 TNF SLPI IL6 IL1B CXCL8
9 chlamydia 32.2 TNF TLR2 IL6 IL1B CXCL8
10 q fever 32.1 TNF TLR2 IL6 IL1B
11 cervical cancer 32.0 TNF IL6 ESR1 CXCL8 CD4 CCR6
12 candidiasis 32.0 TNF TLR2 IL6 IL1B DEFB4A CXCL8
13 trichomoniasis 32.0 TNF SLPI IL6 EPPIN CXCL8 CD4
14 acquired immunodeficiency syndrome 31.9 TNF IL6 IL1B CD4 CCR6 CCR5
15 chronic mucocutaneous candidiasis 31.7 TNF TLR2 IL6 IL1B CD4 CCR6
16 endometritis 31.6 TNF TLR2 SIGLEC5 IL6 IL1B ESR1
17 vaginal disease 31.6 TNF TLR2 SPTB SLPI IL6 IL1B
18 endometriosis 31.4 IL6 IL1B ESR2 ESR1 CXCL8
19 adenomyosis 31.3 ESR2 ESR1 CXCL8
20 endometrial hyperplasia 31.1 ESR2 ESR1 AR
21 bacteriuria 31.0 TLR2 IL6 CXCL8
22 ileus 30.9 TNF IL6 IL1B
23 cervicitis 30.9 TLR2 IL6 DEFB4A CXCL8 CD4
24 oral candidiasis 30.8 SLPI DEFB4A CXCL8 CD4 CCR6
25 ovarian cancer 30.8 TNF SLPI IL6 FN1 ESR2 ESR1
26 acute cystitis 30.8 TNF TLR2 IL6 CXCL8 CD4 CCR6
27 proctitis 30.8 TNF CCR6 ABCB1
28 immune deficiency disease 30.7 TNF IL6 CD4 CCR6 CCR5
29 human immunodeficiency virus type 1 30.7 TNF SLPI IL6 CD4 CCR5
30 diarrhea 30.6 TNF IL6 IL1B CXCL8 ABCB1
31 cellulitis 30.6 TNF IL6 DEFB4A CD4 CCR6
32 estrogen excess 30.6 ESR2 ESR1 EPPIN
33 endometrial stromal sarcoma 30.6 IL6 ESR2 ESR1 CXCL8
34 lichen planus 30.6 TNF IL6 DEFB4A CXCL8
35 toxic shock syndrome 30.5 TNF TLR2 IL6 IL1B CXCL8
36 spinal cord injury 30.5 TNF IL6 CXCL8
37 graft-versus-host disease 30.5 TNF IL6 IL1B
38 peritonitis 30.5 TNF TLR2 IL6 IL1B CXCL8
39 vulvar vestibulitis syndrome 30.5 TNF IL1B ESR1
40 erythema multiforme 30.5 TNF IL6 CXCL8
41 diverticulitis 30.5 TNF IL6 CCR6
42 cerebral palsy 30.4 TNF IL6 IL1B CXCL8
43 conjunctivitis 30.4 TNF IL6 CXCL8
44 brucellosis 30.4 TNF IL6 CXCL8
45 placenta disease 30.4 TNF SPTB IL6 IL1B CXCL8
46 pyelonephritis 30.4 TNF IL6 IL1B CXCL8
47 prostatic hypertrophy 30.3 ESR1 EPPIN AR
48 staphylococcal toxic shock syndrome 30.3 TNF IL1B
49 varicose veins 30.3 TNF IL6 FN1 CXCL8
50 appendicitis 30.3 TNF IL6 IL1B CXCL8

Graphical network of the top 20 diseases related to Vaginitis:

Diseases related to Vaginitis

Symptoms & Phenotypes for Vaginitis

UMLS symptoms related to Vaginitis:

leukorrhea, vaginal pruritus, vaginal odor, vaginal discomfort, vaginal pain or burning

GenomeRNAi Phenotypes related to Vaginitis according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 8.92 CXCL8 ESR1 ESR2 TNF

MGI Mouse Phenotypes related to Vaginitis:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.3 ABCB1 AR CCR5 CCR6 CD4 ESR1
2 homeostasis/metabolism MP:0005376 10.28 ABCB1 AR CCR5 CCR6 CD4 ESR1
3 cardiovascular system MP:0005385 10.27 ABCB1 AR CCR5 CCR6 ESR1 ESR2
4 immune system MP:0005387 10.25 ABCB1 AR CCR5 CCR6 CD4 ESR1
5 digestive/alimentary MP:0005381 10.13 ABCB1 AR CCR5 CD4 ESR1 ESR2
6 mortality/aging MP:0010768 10.1 ABCB1 AR CCR5 CD4 DLAT ESR1
7 adipose tissue MP:0005375 10.05 AR ESR1 ESR2 IL6 SPTB TLR2
8 integument MP:0010771 10.02 AR CD4 ESR1 ESR2 FN1 IL1B
9 liver/biliary system MP:0005370 10.02 ABCB1 AR CCR5 ESR1 ESR2 FN1
10 muscle MP:0005369 9.76 AR CCR5 ESR1 ESR2 FN1 IL6
11 neoplasm MP:0002006 9.61 AR CCR5 ESR1 ESR2 FN1 IL1B
12 nervous system MP:0003631 9.44 ABCB1 AR CCR5 CCR6 CD4 ESR1

Drugs & Therapeutics for Vaginitis

Drugs for Vaginitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 138)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Apricot Approved Phase 4
2 Cranberry Approved, Investigational Phase 4
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
Polyestradiol phosphate Approved Phase 4 28014-46-2
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
Nystatin Approved, Vet_approved Phase 4 1400-61-9 11953884
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
Cefpirome Approved Phase 4 84957-29-9 5479539
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
Metronidazole Approved Phase 4 443-48-1 4173
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
Azithromycin Approved Phase 4 83905-01-5 55185 447043
18 Clindamycin phosphate Phase 4
19 Clindamycin palmitate Phase 4
20 Estradiol 17 beta-cypionate Phase 4
21 Contraceptive Agents Phase 4
22 Estradiol 3-benzoate Phase 4
23 Ionophores Phase 4
24 Polymyxins Phase 4
25 Contraceptives, Oral Phase 4
26 Cephalosporins Phase 4
27 Norgestimate, ethinyl estradiol drug combination Phase 4
28 Contraceptives, Oral, Combined Phase 4
29 Topoisomerase Inhibitors Phase 4
30 Anti-Bacterial Agents Phase 4
31 Anti-Infective Agents Phase 4
32 Estrogens, Conjugated (USP) Phase 4
33 Antiparasitic Agents Phase 4
34 Antiprotozoal Agents Phase 4
35 Antibiotics, Antitubercular Phase 4
36 Hawthorn Phase 4
37 Antitubercular Agents Phase 4
Polymyxin B Approved, Vet_approved Phase 3 1404-26-8
Butoconazole Approved Phase 3 64872-76-0, 64872-77-1 47472
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 3 67-73-2 6215
Terconazole Approved Phase 3 67915-31-5 441383
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
leucovorin Approved Phase 3 58-05-9 6006 143
Sulfadoxine Approved, Investigational Phase 3 2447-57-6 17134
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0 4993
Cefixime Approved, Investigational Phase 3 79350-37-1 54362 5362065
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
Piperaquine Experimental, Investigational Phase 3 4085-31-8 5079497
Dihydroartemisinin Experimental, Investigational Phase 3 71939-50-9 6918483

Interventional clinical trials:

(show top 50) (show all 136)
# Name Status NCT ID Phase Drugs
1 The Effects of Vaginal Estrogen and a Nonhormonal Alternative on the Vaginal and Urinary Microbiome in Women With Genitourinary Syndrome of Menopause: A Randomized Controlled Trial Unknown status NCT02869165 Phase 4 Premarin vaginal cream;Apricot kernel oil
2 A Double-blind,Randomized,Parallel,Placebo-controlled Study of Probiotics Capsule as Supplemental Therapy for Group B Streptococci Infection and Vaginitis During Pregnancy Unknown status NCT01779193 Phase 4
3 A Comparative Open Labeled Clinical Study to Evaluate the Efficacy and Tolerability of Two Different Intravaginal Formulations Containing a Combination of Clindamycin and Clotrimazole in Vaginal Infections Completed NCT01697826 Phase 4 ClinSupV3 -soft gelatin capsule;ClinSupV3ER- Extended release tablet
4 Oral Low-molecular Weight Hyaluronic Acid in the Treatment of Atrophic Vaginitis Completed NCT02014428 Phase 4 Placebo
5 Randomized, Blinded Trial Comparing Vaginal Estrogens on Pelvic Organ Prolapse Patients Completed NCT03032848 Phase 4 Conjugated Estrogen;Promestriene;Estriol;Vaginal Moisturizer - Cream
6 Open Multicenter Clinical Study of the Efficacy of the Local Treatment With Polygynax of Mycotic and/or Bacterial Vaginitis Completed NCT02444481 Phase 4 Polygynax combinaison of polymyxin, Neomycin and Nystatin
7 Periodical Presumptive Treatment of Gonorrhoea in Female Sex Workers: Impact on Prevalence of the Disease in Sex Workers and Their Clients Completed NCT01329588 Phase 4 Monthly antibiotic;Monthly placebo
8 Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration Completed NCT00280514 Phase 4 cefpirome and moxifloxacin administration
9 Immediate Versus Delayed Insertion of the Levonorgestrel-Releasing Intrauterine Device Following Dilation and Evacuation: A Randomized Controlled Trial Completed NCT00475228 Phase 4 Levonorgestrel IUD
10 A National, Multi-central, Open-label, Single-arm, Phase IV Study to Evaluate Efficacy and Safety of Gynomax® XL Ovule in the Treatment of Trichomonal Vaginitis, Bacterial Vaginosis, Candidal Vulvovaginitis and Mixed Vaginal Infections Recruiting NCT03839875 Phase 4 Gynomax® XL Vaginal Ovule
11 The Efficacy and Safety Study of Honghe Fujie Lotion for the Treatment of Bacterial Vaginosis Recruiting NCT03446443 Phase 4 Honghe Fujie lotion;Metronidazole Suppositories
12 IMPLORE Study: Investigation of Microbiomes of Postmenopausal Women Looking for Outcomes and Response to Estrogen Therapy Recruiting NCT03996603 Phase 4 Conjugated Estrogens Cream
13 Controlled, Multicenter, Randomized Parallel Group Pilot Study With 2 Treatment Arms in Non-pregnant Women With Acute Symptomatic Bacterial Vaginosis (BV) Recruiting NCT02042287 Phase 4 Metronidazole
14 The Effect of Antibiotics on Latency in Previable Prelabor Rupture of Membranes Between 18 0/7 and 22 6/7 Weeks Gestational Age Recruiting NCT04047849 Phase 4 Antibiotics, oral Azithromycin and oral Amoxicillin
15 The Impact of HIV on Accelerated Aging in the Female Genital Tract: a Pilot Trial of Topical Estradiol to Improve the Vaginal Microbiome and Symptoms of Vaginal Atrophy in Menopausal Women With HIV Not yet recruiting NCT04079218 Phase 4 Estradiol Vaginal Insert
16 Saginil in Vaginal Cannulas vs. Placebo for the Prevention of Vaginitis in Gynecologic Oncologic Patients Receiving Chemotherapy: a Randomized Controlled Trial. Unknown status NCT01420510 Phase 2, Phase 3 Adelmidrol vaginal gel;Placebo vaginal gel
17 Efficacy and Safety of 2 Low-Dose Regimens of Conjugated Estrogen Cream Administered Vaginally in Postmenopausal Women With Atrophic Vaginitis Completed NCT00137371 Phase 3 PVC (daily for 21 days, 7 days off);PVC (twice weekly)
18 Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Estrogen Deficiency-Derived Atrophic Vaginitis Completed NCT00464971 Phase 3 estradiol, 25 mcg
19 A 12 Month, Open-label, Multi-center Trial to Investigate the Endometrial Safety of Vagifem Low Dose (10ug 17beta-estradiol Vaginal Tablet) in Postmenopausal Women With Atrophic Vaginitis Symptoms Completed NCT00431132 Phase 3 estradiol, 10 mcg
20 A 12 Month Double-blind, Randomized, Parallel-group, Placebo-controlled, Multi-center Trial to Investigate the Efficacy and Safety of Vagifem Low Dose (10 mcg 17beta-estradiol Vaginal Tablet) for the Treatment of Postmenopausal Atrophic Vaginitis Symptoms Completed NCT00108849 Phase 3 estradiol, 10 mcg
21 Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis International, Multicentre, Randomised, Double-blind, Parallel Group Study, Comparative Versus Miconazole Completed NCT02515656 Phase 3 POLYGYNAX®;GYNODAKTARIN®;Placebo
22 Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Cream, 0.01% to Estrace® Estradiol Vaginal Cream 0.01% in Atrophic Vaginitis Completed NCT03294538 Phase 3 Estrace® Cream;Generic Estradiol Cream;Vehicle Cream
23 Clinical Endpoint Therapeutic Equivalence Multi-Site Study Comparing Estradiol Vaginal Cream (0.01%; Alvogen Pine Brook LLC.) to Estrace® Cream (0.01%; Warner Chilcott) in Postmenopausal Females With Atrophic Vaginitis Completed NCT02995694 Phase 3 Estradiol;Placebos;Reference
24 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Comparing the Efficacy and Safety of 17-Beta Estradiol 10 Micrograms and 25 Micrograms (Vagifem) Doses in Treatment of Estrogen Deficiency-Derived Atrophic Vaginitis Completed NCT00465192 Phase 3 estradiol, 10 mcg;estradiol, 25 mcg;placebo
25 Clinical Endpoint Therapeutic Equivalence Multi-Site Study Comparing Estradiol Vaginal Cream (0.01%; Mylan) to Estrace® Cream (0.01%; Warner Chilcott) in Postmenopausal Females With Atrophic Vaginitis Completed NCT02195986 Phase 3 Estradiol Vaginal Cream, 0.01%;Estrace® 0.01% cream;Placebo Vaginal Cream
26 An Investigator-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of Estradiol Vaginal Inserts, USP 10 mcg and Vagifem® (Estradiol Vaginal Tablets) 10 mcg and Compare Both Active Treatments to a Placebo Control in Female Subjects With Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy Associated With Menopause Completed NCT01779947 Phase 3 Estradiol Vaginal Tablets 10 mcg;placebo
27 Vaginal Infection Study Completed NCT00616330 Phase 3 clindamycin phosphate/butoconazole nitrate;clindamycin phosphate;butoconazole nitrate
28 Intravaginal Treatment of Disturbances of Vaginal Flora Among HIV Infected and Uninfected Women in Malawi Completed NCT00140764 Phase 3 Metronidazole gel versus placebo gel
29 Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause Completed NCT02013544 Phase 3 Placebo;Prasterone (DHEA)
30 Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy Completed NCT01358760 Phase 3 Placebo;DHEA;DHEA
31 DHEA Against Vaginal Atrophy - Safety Study of 12 Months Completed NCT01256671 Phase 3 DHEA
32 Trichomonas Vaginalis Repeat Infections Among HIV Negative Women Completed NCT01832480 Phase 3 MTZ 500 mg twice daily x 7 days;MTZ 2 g
33 A Prospective, Open-Label, Comparative, Parallel Double-Arm, Multicentric Clinical Study to Evaluate the Efficacy of an Ovule With Triple Active Agents (Terconazole, Clindamycin, Fluocinolone) Administered Once Per Day for Three Days Versus an Ovule With Triple Active Agents (Metronidazole, Nystatin, Fluocinolone) Administered Once Per Day for Ten Days to Treat Secondary Vulvar/Vaginal Symptoms of Vaginitis/Infectious Vaginosis (Bacterial and/or Mycotic and/or Parasitic) Completed NCT01867164 Phase 3 Gynoclin V;Vagitrol V
34 A Randomised Controlled Trial of Single Dose Tinidazole+Fluconazole Versus Longer Courses of Metronidazole+Clotrimazole in the Management of West African Women With Vaginal Discharge Completed NCT00313131 Phase 3 tinidazole+fluconazole vs metronidazole+clotrimazole
35 DHEA Against Vaginal Atrophy (Placebo-controlled, Double-blind and Randomized Phase III Study of 3-month Intravaginal DHEA) Completed NCT01256684 Phase 3 Placebo;DHEA;DHEA
36 The Effects of Local Vaginal Estrogen in Postmenopausal Women With Pelvic Organ Prolapse: A Randomized Control Trial Completed NCT00803335 Phase 3 Vaginal conjugated estrogen cream 0.5gm;Vaginal conjugated estrogen cream 1.0gm
37 Topical DHEA Against Vaginal Atrophy (3-Month Placebo-Controlled Double-Blind Randomized Phase III Study) Completed NCT01846442 Phase 3 Placebo;DHEA (0.25%);DHEA (0.5%);DHEA (1.0%)
38 Assiut University Hospital - Women Health Hospital Completed NCT02365389 Phase 2, Phase 3 MTZ vaginal gel;Conventional MTZ vaginal gel
39 A Phase II/III Multicenter, Randomized, Double-masked, Study of the Safety and Contraceptive Efficacy of C31G Compared to Conceptrol® Completed NCT00274261 Phase 3 C31G;nonoxynol-9 (N-9)
40 A Phase III Trial of Placebo Versus Megestrol Acetate 20 MG/Day Versus Megestrol Acetate 40 MG/Day as Treatment for Symptoms of Ovarian Failure in Women Treated for Breast Cancer: SWOG Study S9626 Completed NCT00005975 Phase 3 Megestrol Acetate 20mg/day;Megestrol Acetate 40 mg/day;Megestrol Acetate Placebo 20 mg/day;Megestrol Acetate Placebo 40 mg/day
41 Home Screening for Bacterial Vaginosis to Prevent STDs Completed NCT00667368 Phase 3 Metronidazole
42 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) Compared to Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC) Recruiting NCT04029116 Phase 3 Fluconazole Tablet;IBREXAFUNGERP;Placebo oral tablet
43 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (AVVC). Recruiting NCT03987620 Phase 3 Ibrexafungerp;Placebo
44 Effects of Metronidazole Plus Intermittent Preventive Treatment of Malaria in Pregnancy on Birth Outcomes: a Randomised Controlled Trial in Zambia Not yet recruiting NCT04189744 Phase 3 IPTp-sulphadoxine-pyrimethamine plus metronidazole;IPTp-dihydroartemisinin-piperaquine plus metronidazole;IPTp-sulphadoxine-pyrimethamine
45 A Randomized Controlled Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis Terminated NCT00816556 Phase 3 Estriol;Estradiol valerate;Vanicream Lite
47 A Randomized Trial to Evaluate the Need for Empiric Therapy for Mucopurulent Cervicitis of Unknown Etiology Terminated NCT01072136 Phase 3 Azithromycin;Cefixime
48 Comparative Study of the Efficacy and Safety of LactiSal 1% Vaginal Gel and LactSal 50 mg Vaginal Tablet Versus Clotrimazole 100 mg Vaginal Tablet in the Treatment of Vulvovaginal Candidiasis (VVC) Withdrawn NCT02907307 Phase 3 Clotrimazole vaginal tablet 100mg
49 Effect of Intravaginal Prasterone (DHEA) on Moderate to Severe Symptoms of Vulvovaginal Atrophy Due to Menopause, in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer - (Placebo-Controlled, Double Blind and Randomized Phase III Study) Withdrawn NCT03740945 Phase 3 Placebo;Prasterone (DHEA)
50 A Double-blind, Randomized, Placebo-controlled, Parallel Design, Multicenter Phase II Trial to Evaluate the Efficacy and Safety of HUDC_VT in Patients With Bacterial Vaginosis Unknown status NCT03357666 Phase 2 HUDC_VT(Glucose 200mg/Sodium chloride 200mg);HUDC_VT (Glucose 400mg/Sodium chloride 200mg);HUDC_VT (Glucose 400mg);HUDC_VT (Sodium chloride 200mg);Placebo

Search NIH Clinical Center for Vaginitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cochrane evidence based reviews: vaginitis

Genetic Tests for Vaginitis

Anatomical Context for Vaginitis

MalaCards organs/tissues related to Vaginitis:

Testes, Breast, Heart, Colon, Cervix, Skin, Uterus

Publications for Vaginitis

Articles related to Vaginitis:

(show top 50) (show all 3433)
# Title Authors PMID Year
Vaginal yeast colonisation: From a potential harmless condition to clinical implications and management approaches-A literature review. 61 42
31038771 2019
The safety of oral fluconazole during the first trimester of pregnancy: a systematic review and meta-analysis. 42
31446677 2019
50 Years Ago in The Journal of Pediatrics: Vulvovaginitis in the Premenarcheal Child. 42
30798826 2019
Antiviral effect of Chinese herbal prescription JieZe-1 on adhesion and penetration of VK2/E6E7 with herpes simplex viruses type 2. 61
31743766 2020
Mycoplasma genitalium prevalence in Welsh sexual health patients: Low antimicrobial resistance markers and no association of symptoms to bacterial load. 61
31756372 2020
Noncandidal vaginitis: a comprehensive approach to diagnosis and management. 61
31513780 2020
Multimodality Screening for Lower Genital Tract Infections Between 18 and 24 Weeks of Pregnancy and its Efficacy in Predicting Spontaneous Preterm Delivery. 61
32030004 2020
Association between Vaginal Micro-environment Disorder and Cervical Intraepithelial Neoplasia in a Community Based Population in China. 61
31897224 2020
Clinical Validation of the Aptima Bacterial Vaginosis and Aptima Candida/Trichomonas Vaginitis Assays: Results from a Prospective Multicenter Clinical Study. 61
31748322 2020
Prognosis and Long-Term Outcome of Women With Idiopathic Recurrent Vulvovaginal Candidiasis Caused by Candida albicans. 61
31860575 2020
In vitro anticandidal potency of Syzygium aromaticum (clove) extracts against vaginal candidiasis. 61
32020877 2020
Diagnostic performance of two molecular assays for the detection of vaginitis in symptomatic women. 61
31502121 2020
Fluconazole Prophylaxis in Prevention of Symptomatic Candida Vaginitis. 61
31965356 2020
Vaginitis in Nonpregnant Patients: ACOG Practice Bulletin Summary, Number 215. 61
31856118 2020
Vaginitis in Nonpregnant Patients: ACOG Practice Bulletin, Number 215. 61
31856123 2020
Vaginal bacterial profiles of aerobic vaginitis: a case-control study. 61
31955954 2020
The need for better evidence to support probiotics for vaginitis. 61
31446672 2020
Blue light therapy to treat candida vaginitis with comparisons of three wavelengths: an in vitro study. 61
31900692 2020
The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysis. 61
31522958 2019
Critical analysis of methods for assessing genitourinary syndrome of menopause used in clinical trials. 61
31644509 2019
What you should know about emphysematous vaginitis? 61
31893110 2019
Prospective Evaluation of Molecular Assays for Diagnosis of Vaginitis. 61
31694966 2019
Evaluating the Impact of a Student-Run Women's Clinic on Access to Gynecologic Care for Uninsured Women in Rhode Island. 61
31795536 2019
Rapid differential diagnosis of vaginal infections using gold nanoparticles coated with specific antibodies. 61
31183547 2019
Alleviation of vulvovaginitis symptoms: can probiotics lead the treatment plan? 61
31965832 2019
Epidemiology and resistance trends of Staphylococcus aureus isolated from vaginal samples: a 10-year retrospective study in Hungary. 61
31855266 2019
Knot positioning during McDonald cervical cerclage, does it make a difference? A cohort study. 61
29764255 2019
Stump Pyometra Secondary to Human Topical Estrogen Hormone Exposure in a Spayed Female Chihuahua. 61
31525086 2019
Vulvar Diseases Part II: Conditions in adults and children. 61
31712170 2019
Renal and vaginal calculi in a free-ranging long-beaked common dolphin Delphinus capensis. 61
31724559 2019
The Burden of Fungal Infections in Ethiopia. 61
31771096 2019
Looking for appropriateness in the cure of mixed vaginitis: the role of fenticonazole as an empiric treatment. 61
31845594 2019
Candida vaginitis among symptomatic pregnant women attending antenatal clinics in Mwanza, Tanzania. 61
31775911 2019
Simultaneous Determination of Six Compounds in Destructive Distillation Extracts of Hawthorn Seed by GC-MS and Evaluation of Their Antimicrobial Activity. 61
31783502 2019
Use of probiotics in medical devices applied to some common pathologies. 61
31850866 2019
Cervical cancer and vaginal microbiota changes. 61
31659380 2019
Group A Streptococcal Vulvitis in Adult Women: Clinical Features and Association With Psoriasis. 61
31592977 2019
[Analysis of common gynecological diseases in 1142 married female workers]. 61
31726513 2019
Bacterial vaginosis, vulvovaginal candidiasis and trichomonal vaginitis among reproductive-aged women seeking primary healthcare in Sana'a city, Yemen. 61
31640583 2019
Inhibition of Candidaalbicans and induced vaginitis by sapindus water extract. 61
31651193 2019
The role of the miR1976/CD105/integrin αvβ6 axis in vaginitis induced by Escherichia coli infection in mice. 61
31594987 2019
A Cross-Sectional Study on the Dermatoses in Postmenopausal Patients at a Rural-Based Tertiary Health Care Center. 61
31543529 2019
Hormonal Contraception and Vaginal Infections Among Couples Who Are Human Immunodeficiency Virus Serodiscordant in Lusaka, Zambia. 61
31403592 2019
Transcriptome Profiling Analysis of Bovine Vaginal Epithelial Cell Response to an Isolated Lactobacillus Strain. 61
31506261 2019
Celiac disease in the context of airborne allergen-associated chronic vulvo-vaginitis. 61
31599434 2019
Molecular Diagnosis of Vaginitis: Comparing Quantitative PCR and Microbiome Profiling Approaches to Current Microscopy Scoring. 61
31315951 2019
Martius flap reconstruction for rectovaginal fistula after stapled hemorrhoidopexy (Longo operation): a case report. 61
31378835 2019
Berberine exhibits antioxidative effects and reduces apoptosis of the vaginal epithelium in bacterial vaginosis. 61
31410167 2019
Pharmacokinetics of vaginal progesterone in pregnancy. 61
31211965 2019
Correlation between cervical carcinogenesis and tobacco use by sexual partners. 61
31802062 2019

Variations for Vaginitis

Expression for Vaginitis

Search GEO for disease gene expression data for Vaginitis.

Pathways for Vaginitis

Pathways related to Vaginitis according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
13.85 TNF IL6 IL1B FN1 ESR2 ESR1
Show member pathways
Show member pathways
Show member pathways
Show member pathways
7 12.87 IL6 FN1 ESR2 ESR1 CXCL8 AR
Show member pathways
Show member pathways
Show member pathways
12.63 TNF TLR2 IL6 IL1B CD4
Show member pathways
12.62 TNF IL6 IL1B FN1 CD4
Show member pathways
12.61 TNF TLR2 IL6 IL1B CD4 CCR5
Show member pathways
Show member pathways
15 12.32 TNF TLR2 FN1 ESR1
16 12.31 TNF IL6 IL1B CXCL8
Show member pathways
Show member pathways
12.28 TNF TLR2 IL6 CXCL8
Show member pathways
12.28 TNF TLR2 IL1B CCR5
20 12.26 TNF IL6 IL1B DEFB4A CXCL8
21 12.25 TNF TLR2 IL6 IL1B
Show member pathways
23 12.09 TNF IL6 IL1B ESR2 CXCL8 AR
Show member pathways
12.07 TNF TLR2 IL6 IL1B CD4
25 12.05 TNF IL6 IL1B CXCL8
Show member pathways
12.03 TNF TLR2 IL6 IL1B FN1
27 12 TNF IL6 IL1B FN1 CXCL8
28 11.98 IL6 IL1B FN1 CXCL8
29 11.97 TNF IL6 IL1B FN1 CXCL8
30 11.94 TNF IL6 IL1B CD4
31 11.89 TNF IL6 IL1B FN1 CXCL8
32 11.84 TNF IL1B CD4 CCR6
33 11.82 TNF TLR2 IL6 IL1B CXCL8
34 11.8 TNF IL6 IL1B CXCL8
35 11.79 IL6 IL1B CXCL8
36 11.79 TNF IL6 IL1B CD4
37 11.74 TNF IL6 IL1B
Show member pathways
11.68 TNF IL6 IL1B CXCL8
39 11.68 TNF IL6 IL1B CXCL8
40 11.55 TNF TLR2 IL1B
41 11.55 TNF IL6 FN1
42 11.5 TNF IL6 IL1B AR
43 11.48 TNF TLR2 IL6 IL1B CXCL8
44 11.44 TNF TLR2 IL6 IL1B FN1 CXCL8
45 11.42 TNF IL6 IL1B
46 11.39 TNF IL6 IL1B
Show member pathways
48 11.35 TNF TLR2 IL6 IL1B CXCL8
49 11.34 TNF IL6 IL1B
50 11.33 TNF IL6 IL1B

GO Terms for Vaginitis

Cellular components related to Vaginitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.17 TNF TLR2 EPPIN CD4 CCR6 CCR5
2 sperm plasma membrane GO:0097524 8.96 EPPIN CCR6

Biological processes related to Vaginitis according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.21 TLR2 IL6 IL1B ESR2 ESR1 CXCL8
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.19 TNF TLR2 IL6 IL1B ESR1 ATAD2
3 negative regulation of cell proliferation GO:0008285 10.05 TLR2 IL6 IL1B CXCL8 AR
4 positive regulation of gene expression GO:0010628 10 TNF TLR2 IL6 IL1B FN1 AR
5 cell-cell signaling GO:0007267 9.96 IL1B ESR2 CCR5 AR
6 inflammatory response GO:0006954 9.95 TNF TLR2 IL6 IL1B CXCL8 CCR5
7 chemotaxis GO:0006935 9.92 DEFB4A CXCL8 CCR6 CCR5
8 defense response GO:0006952 9.91 TNF DEFB4A CXCL8 CCR5
9 defense response to Gram-positive bacterium GO:0050830 9.84 TNF TLR2 IL6 DEFB4A
10 chemokine-mediated signaling pathway GO:0070098 9.83 CXCL8 CCR6 CCR5
11 cellular response to lipopolysaccharide GO:0071222 9.83 TNF IL6 IL1B CXCL8 CCR5
12 positive regulation of T cell proliferation GO:0042102 9.82 IL6 IL1B CD4
13 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.81 TNF TLR2 IL1B
14 humoral immune response GO:0006959 9.8 TNF IL6 CCR6
15 positive regulation of interleukin-6 secretion GO:2000778 9.76 TNF TLR2 IL1B
16 positive regulation of transcription, DNA-templated GO:0045893 9.76 TNF IL6 IL1B ESR2 ESR1 CD4
17 lipopolysaccharide-mediated signaling pathway GO:0031663 9.75 TNF TLR2 IL1B
18 negative regulation of neurogenesis GO:0050768 9.73 TNF IL6 IL1B
19 positive regulation of interleukin-8 production GO:0032757 9.72 TNF TLR2 IL1B
20 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.72 TNF TLR2 IL6 IL1B AR
21 positive regulation of interleukin-6 production GO:0032755 9.71 TNF TLR2 IL6 IL1B
22 positive regulation of chemokine biosynthetic process GO:0045080 9.67 TNF IL1B
23 positive regulation of chemokine production GO:0032722 9.67 TNF TLR2 IL6
24 negative regulation of lipid storage GO:0010888 9.65 TNF IL6
25 positive regulation of DNA-binding transcription factor activity GO:0051091 9.65 TNF IL6 IL1B ESR2 ESR1
26 regulation of establishment of endothelial barrier GO:1903140 9.63 TNF IL1B
27 fusion of virus membrane with host plasma membrane GO:0019064 9.63 CD4 CCR5
28 positive regulation of glial cell proliferation GO:0060252 9.63 TNF IL6 IL1B
29 positive regulation of fever generation GO:0031622 9.61 TNF IL1B
30 sequestering of triglyceride GO:0030730 9.6 TNF IL1B
31 entry into host cell GO:0030260 9.59 CD4 CCR5
32 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.57 TNF IL1B
33 positive regulation of neuroinflammatory response GO:0150078 9.54 TNF IL6 IL1B
34 cytokine-mediated signaling pathway GO:0019221 9.5 TNF IL6 IL1B FN1 CXCL8 CD4
35 immune response GO:0006955 9.32 TNF TLR2 SLPI IL6 IL1B DEFB4A

Molecular functions related to Vaginitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.98 TNF TLR2 FN1 ESR2 ESR1 DLAT
2 cytokine activity GO:0005125 9.76 TNF IL6 IL1B CXCL8
3 protein binding GO:0005515 9.62 TNF TLR2 SPTB SLPI SIGLEC5 IL6
4 steroid hormone receptor activity GO:0003707 9.58 ESR2 ESR1 AR
5 nuclear receptor activity GO:0004879 9.5 ESR2 ESR1 AR
6 enzyme binding GO:0019899 9.43 SLPI FN1 ESR2 ESR1 CD4 AR
7 estrogen receptor activity GO:0030284 9.37 ESR2 ESR1
8 steroid binding GO:0005496 9.33 ESR2 ESR1 AR
9 estrogen response element binding GO:0034056 9.26 ESR2 ESR1

Sources for Vaginitis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....